Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31348058 | 0.64 | KMT2A (0.50) | KMT2AMEN1NOX1KDM4EPOLB | |
| SCHEMBL10278599 | 0.63 | CA1 (0.53) | KMT2AMEN1NOX1KDM4EPOLB | |
| SCHEMBL4707719 | 0.60 | NOX1 (0.43) | KMT2AMEN1NOX1POLBMAPT | |
| SCHEMBL20664932 | 0.60 | KMT2A (0.46) | KMT2AMEN1NOX1KDM4EPOLB | |
| SCHEMBL22941400 | 0.58 | GPR3 (0.38) | KMT2AMEN1NOX1MAPT | |
| SCHEMBL4708571 | 0.57 | — | — | |
| SCHEMBL356698 | 0.54 | AHR (0.50) | POLBMAPTCA1CA2CA4 | |
| SCHEMBL29697204 | 0.54 | S100A4 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL29726026 | 0.54 | S100A4 (0.46) | CA12CA1CA2CA4CA7 | |
| SCHEMBL31602107 | 0.49 | CHEK1 (0.53) | CA12CA1CA2CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765797-A4 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | UNIV KANSAS CT FOR RES INC (US) | 2008-02-06 | — | — | EP | claimed |
| EP-1765797-A1 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | University of Kansas Center for Research, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| WO-2006002441-A1 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | UNIVERSITY OF KANSAS (US) | 2006-01-05 | — | — | WO | claimed |
| US-20050288279-A1 | Phenothiazine derivatives and their method of use | KANSAS MEDICAL CENTER, UNIVERSITY OF | 2005-12-29 | — | — | US | claimed |
| EP-1765797-A4 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | UNIV KANSAS CT FOR RES INC (US) | 2008-02-06 | — | — | EP | disclosed |
| EP-1765797-A1 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | University of Kansas Center for Research, Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006002441-A1 | PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE | UNIVERSITY OF KANSAS (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20050288279-A1 | Phenothiazine derivatives and their method of use | KANSAS MEDICAL CENTER, UNIVERSITY OF | 2005-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288279-A1 | Phenothiazine derivatives and their method of use | SHBG, GPR119, BRDT | KMT2A 1178/4885MEN1 2558/4885NOX1 3177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.